A sting in the tail: the N-terminal domain of the androgen receptor as a drug target

The role of androgen receptor (AR) in the initiation and progression of prostate cancer (PCa) is well established. Competitive inhibition of the AR ligand-binding domain (LBD) has been the staple of antiandrogen therapies employed to combat the disease in recent years. However, their efficacy has of...

Full description

Bibliographic Details
Main Authors: Amy E Monaghan, Iain J McEwan
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Asian Journal of Andrology
Subjects:
Online Access:http://www.ajandrology.com/article.asp?issn=1008-682X;year=2016;volume=18;issue=5;spage=687;epage=694;aulast=Monaghan
id doaj-f712fed545034160a14ba893e466f7a3
record_format Article
spelling doaj-f712fed545034160a14ba893e466f7a32020-11-24T22:32:49ZengWolters Kluwer Medknow PublicationsAsian Journal of Andrology1008-682X1745-72622016-01-0118568769410.4103/1008-682X.181081A sting in the tail: the N-terminal domain of the androgen receptor as a drug targetAmy E MonaghanIain J McEwanThe role of androgen receptor (AR) in the initiation and progression of prostate cancer (PCa) is well established. Competitive inhibition of the AR ligand-binding domain (LBD) has been the staple of antiandrogen therapies employed to combat the disease in recent years. However, their efficacy has often been limited by the emergence of resistance, mediated through point mutations, and receptor truncations. As a result, the prognosis for patients with malignant castrate resistant disease remains poor. The amino-terminal domain (NTD) of the AR has been shown to be critical for AR function. Its modular activation function (AF-1) is important for both gene regulation and participation in protein-protein interactions. However, due to the intrinsically disordered structure of the domain, its potential as a candidate for therapeutic intervention has been dismissed in the past. The recent emergence of the small molecule EPI-001 has provided evidence that AR-NTD can be targeted therapeutically, independent of the LBD. Targeting of AR-NTD has the potential to disrupt multiple intermolecular interactions between AR and its coregulatory binding partners, in addition to intramolecular cross-talk between the domains of the AR. Therapeutics targeting these protein-protein interactions or NTD directly should also have efficacy against emerging AR splice variants which may play a role in PCa progression. This review will discuss the role of intrinsic disorder in AR function and illustrate how emerging therapies might target NTD in PCa.http://www.ajandrology.com/article.asp?issn=1008-682X;year=2016;volume=18;issue=5;spage=687;epage=694;aulast=Monaghanandrogen receptor; inhibitor; intrinsically disordered structure; N-terminal domain; prostate cancer; small molecules
collection DOAJ
language English
format Article
sources DOAJ
author Amy E Monaghan
Iain J McEwan
spellingShingle Amy E Monaghan
Iain J McEwan
A sting in the tail: the N-terminal domain of the androgen receptor as a drug target
Asian Journal of Andrology
androgen receptor; inhibitor; intrinsically disordered structure; N-terminal domain; prostate cancer; small molecules
author_facet Amy E Monaghan
Iain J McEwan
author_sort Amy E Monaghan
title A sting in the tail: the N-terminal domain of the androgen receptor as a drug target
title_short A sting in the tail: the N-terminal domain of the androgen receptor as a drug target
title_full A sting in the tail: the N-terminal domain of the androgen receptor as a drug target
title_fullStr A sting in the tail: the N-terminal domain of the androgen receptor as a drug target
title_full_unstemmed A sting in the tail: the N-terminal domain of the androgen receptor as a drug target
title_sort sting in the tail: the n-terminal domain of the androgen receptor as a drug target
publisher Wolters Kluwer Medknow Publications
series Asian Journal of Andrology
issn 1008-682X
1745-7262
publishDate 2016-01-01
description The role of androgen receptor (AR) in the initiation and progression of prostate cancer (PCa) is well established. Competitive inhibition of the AR ligand-binding domain (LBD) has been the staple of antiandrogen therapies employed to combat the disease in recent years. However, their efficacy has often been limited by the emergence of resistance, mediated through point mutations, and receptor truncations. As a result, the prognosis for patients with malignant castrate resistant disease remains poor. The amino-terminal domain (NTD) of the AR has been shown to be critical for AR function. Its modular activation function (AF-1) is important for both gene regulation and participation in protein-protein interactions. However, due to the intrinsically disordered structure of the domain, its potential as a candidate for therapeutic intervention has been dismissed in the past. The recent emergence of the small molecule EPI-001 has provided evidence that AR-NTD can be targeted therapeutically, independent of the LBD. Targeting of AR-NTD has the potential to disrupt multiple intermolecular interactions between AR and its coregulatory binding partners, in addition to intramolecular cross-talk between the domains of the AR. Therapeutics targeting these protein-protein interactions or NTD directly should also have efficacy against emerging AR splice variants which may play a role in PCa progression. This review will discuss the role of intrinsic disorder in AR function and illustrate how emerging therapies might target NTD in PCa.
topic androgen receptor; inhibitor; intrinsically disordered structure; N-terminal domain; prostate cancer; small molecules
url http://www.ajandrology.com/article.asp?issn=1008-682X;year=2016;volume=18;issue=5;spage=687;epage=694;aulast=Monaghan
work_keys_str_mv AT amyemonaghan astinginthetailthenterminaldomainoftheandrogenreceptorasadrugtarget
AT iainjmcewan astinginthetailthenterminaldomainoftheandrogenreceptorasadrugtarget
AT amyemonaghan stinginthetailthenterminaldomainoftheandrogenreceptorasadrugtarget
AT iainjmcewan stinginthetailthenterminaldomainoftheandrogenreceptorasadrugtarget
_version_ 1725732237558677504